Prof. Apostolos Zaravinos – Cancer Genetics – Excellence in Research

Published on by Oncology

Prof. Apostolos Zaravinos - Cancer Genetics - Excellence in Research

European University Cyprus - Cyprus

Author Profile

Google Scholar

Orcid

Scopus

EARLY ACADEMIC PURSUITS

Dr. Apostolos Zaravinos began his academic journey with a B.Sc. in Molecular Biology from the Department of Biology at the University of Crete in 2004. He further pursued his passion for medicine by obtaining his Ph.D. in Medicine from the Medical School of the same university in 2008. These foundational academic pursuits laid the groundwork for his subsequent research and professional endeavors in the field of cancer genetics and molecular biology.

PROFESSIONAL ENDEAVORS

After completing his Ph.D., Dr. Zaravinos embarked on a series of professional roles that enriched his expertise and contributed to the scientific community. He worked as a Research Scientist at the Harris Birthright Research Center for Fetal Medicine at King’s College Hospital from 2009 to 2010. Subsequently, he performed postdoctoral research in Cancer Genetics at the Molecular Medicine Research Center of the University of Cyprus from 2011 to 2013. He further honed his skills in Immunogenetics and Cancer Genetics during his postdoctoral training at the Department of Laboratory Medicine of the Karolinska Institute from 2013 to 2015.In 2015, Dr. Zaravinos was appointed as an Assistant Professor of Cancer Genetics at the European University Cyprus. He was promoted to the rank of Associate Professor in 2019. He also served as an Associate Professor of Genetics at the Department of Basic Medical Science, College of Medicine (CMED) at Qatar University from 2020 to 2021. These academic positions allowed him to mentor students, lead research projects, and contribute to the advancement of cancer genetics and immunogenetics.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER GENETICS

Dr. Zaravinos' research contributions are significant and multifaceted. His primary research aim is to achieve an advanced understanding of carcinogenesis by investigating interactions between genes. He is particularly interested in Cancer Immunogenetics and aims to elucidate how the tumor microenvironment relates to different aspects of tumor biology. His research has focused on examining the immune landscape of inflamed tumors, including colorectal cancer and skin melanoma, using next-generation sequencing approaches.

IMPACT AND INFLUENCE

Dr. Zaravinos has made a substantial impact on the field of cancer genetics and immunogenetics. He has authored over 125 original research articles and 7 book chapters, demonstrating his prolific research output. His work has been cited over 3,600 times, with an h-index of 35, as documented on Scopus. His research findings have contributed to the scientific community's understanding of carcinogenesis, tumor immunology, and the tumor microenvironment.

ACADEMIC CITES

Dr. Zaravinos' research has garnered significant attention and recognition in the scientific community, as evidenced by his high citation count and h-index. His publications have been cited over 3,600 times, highlighting the impact and relevance of his research in the field of cancer genetics and immunogenetics.

LEGACY AND FUTURE CONTRIBUTIONS

Dr. Zaravinos' legacy in the field of cancer genetics and immunogenetics is characterized by his groundbreaking research, mentorship, and contributions to scientific literature. His work has paved the way for future research endeavors aimed at understanding carcinogenesis, tumor immunology, and the tumor microenvironment. As a dedicated researcher and educator, Dr. Zaravinos continues to inspire and influence the next generation of scientists, leaving a lasting impact on the field of cancer genetics and molecular biology. His future contributions are eagerly anticipated as he continues to explore new avenues in cancer research and mentor emerging scientists in the field.

NOTABLE PUBLICATIONS

Regulation of PD-L1 Expression by YY1 in Cancer: Therapeutic Efficacy of Targeting YY1. 2024

Peptide absent sequences emerging in human cancers. 2024

Immune Cytolytic Activity and Strategies for Therapeutic Treatment. 2024

Strand asymmetries across genomic processes. 2023

Tumor mutation burden in the prognosis and response of lung cancer patients to immune-checkpoint inhibition therapies. 2023 (3)

 

Aya H. Soliman – Tumor Immunology – Best Researcher Award

Published on by Oncology

Ms.Aya H. Soliman - Tumor Immunology - Best Researcher Award

German University in Cairo - Egypt

AUTHOR PROFILE

Scopus

Orcid 

EARLY ACADEMIC PURSUITS:

Aya H. Soliman's academic journey commenced with a fervent pursuit of knowledge. Her early years were marked by a dedication to learning, demonstrating an insatiable curiosity and a penchant for academic excellence. Whether it be notable achievements, academic milestones, or early influences, this period laid the foundation for her future endeavors.

PROFESSIONAL ENDEAVORS:

Embarking on a path of professional growth, Soliman transitioned seamlessly from academia to the professional realm. Her career trajectory reflects a commitment to applying theoretical knowledge to real-world challenges. A closer examination of her professional undertakings unveils a strategic and purposeful approach to making significant contributions in her chosen field.

CONTRIBUTIONS AND RESEARCH FOCUS ON TUMOR IMMUNOLOGY

Soliman's contributions to her field are nothing short of groundbreaking. Her research focus is characterized by a meticulous exploration of pertinent issues, coupled with innovative methodologies. By delving into specific themes, she has enriched the academic landscape with fresh perspectives and novel insights, leaving an indelible mark on her area of expertise.

IMPACT AND INFLUENCE:

The impact of Soliman's work extends far beyond the confines of academia. Her research and professional activities have influenced not only fellow scholars but also practitioners in the field. By contributing to the advancement of knowledge, she has played a pivotal role in shaping industry practices and policies, showcasing a far-reaching influence.

ACADEMIC CITES:

A quantitative measure of Soliman's academic influence lies in the citation of her work. The number of times her research has been referenced underscores its significance within scholarly discourse. Her contributions have become integral to the academic canon, with citations serving as a testament to the enduring relevance of her ideas.

FUTURE CONTRIBUTIONS:

Looking ahead, Soliman's future contributions hold promise for continued innovation and advancement. Anticipating the evolving landscape of her field, she remains poised to address emerging challenges and contribute novel solutions. The trajectory of her future contributions is eagerly awaited, promising to shape the direction of academic and professional discourse.

Notable Publications

Phytochemical-derived tumor-associated macrophage remodeling strategy using Phoenix dactylifera L. boosted photodynamic therapy in melanoma via H19/iNOS/PD-L1 axis. 2023

 

 

Medical Oncology

Published on by Oncology

Medical Oncology

Introduction to Medical Oncology: Medical Oncology is a specialized branch of medicine dedicated to the diagnosis, treatment, and management of cancer. This field plays a pivotal role in improving the lives of cancer patients through various treatment modalities and cutting-edge research. Within the realm of Medical Oncology, several key subtopics are essential for understanding and addressing the complexities of cancer care:

Chemotherapy and Targeted Therapies: Chemotherapy involves the use of drugs to kill or slow the growth of cancer cells, while targeted therapies focus on specific molecular abnormalities within cancer cells. Understanding these treatment options is crucial for medical oncologists to tailor therapies for individual patients.

Immunotherapy: Immunotherapy harnesses the body’s immune system to combat cancer. This groundbreaking approach has revolutionized cancer treatment by enhancing the body’s natural defenses against cancer cells.

Precision Medicine: Precision medicine in oncology involves customizing treatment plans based on a patient’s unique genetic and molecular profile. It allows for more personalized and effective cancer treatments, minimizing side effects.

Palliative Care: Palliative care in Medical Oncology is vital for improving the quality of life for cancer patients. It focuses on symptom management, pain relief, and emotional support to enhance patients’ overall well-being.

Clinical Trials and Research: Ongoing research and clinical trials are at the forefront of Medical Oncology. Investigating new treatments, therapies, and breakthroughs in cancer care is essential for improving patient outcomes and advancing the field.

These subtopics illustrate the multidimensional nature of Medical Oncology, where a comprehensive approach is taken to address the complexities of cancer treatment and patient care.